Cell line/type | BM-MSCs (Bone marrow-derived mesenchymal stromal cells) |
---|---|
Species | Human |
Animal free | Yes |
Product | PRIME-XV serum-free medium |
Heathman, T. R., Stolzing, A., Fabian, C., Rafiq, Q. A., Coopman, K., Nienow, A. W., ... & Hewitt, C. J. (2015). Serum-free process development: improving the yield and consistency of human mesenchymal stromal cell production. Cytotherapy, 17(11), 1524-1535. In this study, bone marrow-derived hMSCs (BM-hMSCs) from two donors were expanded for 36 days in monolayer with medium supplemented with either fetal bovine serum (FBS) or PRIME-XV serum-free medium (SFM). Cells were assessed throughout culture for proliferation, mean cell diameter, colony-forming potential, osteogenic potential, gene expression and metabolites. Expansion of BM-hMSCs in PRIME-XV SFM resulted in a significantly higher growth rate (P < 0.001) and increased consistency between donors compared with FBS-based culture. FBS-based culture showed an inter-batch production range of 0.9 and 5 days per dose compared with 0.5 and 0.6 days in SFM for each BM-hMSC donor line. The consistency between donors was also improved by the use of PRIME-XV SFM, with a production range of 0.9 days compared with 19.4 days in FBS-based culture. Mean cell diameter has also been demonstrated as a process metric for BM-hMSC growth rate and senescence through a correlation (R(2) = 0.8705) across all conditions. PRIME-XV SFM has also shown increased consistency in BM-hMSC characteristics such as per cell metabolite utilization, in vitro colony-forming potential and osteogenic potential despite the higher number of population doublings. PRIME-XV serum-free medium is a commercial product. The formulation is proprietary. https://www.sciencedirect.com/science/article/pii/S1465324915010233 |
|
Source | Literature - modified commercial product |
Chemically defined > Unspecified | Unspecified |